BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35976089)

  • 21. The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.
    Santema BT; Chan MMY; Tromp J; Dokter M; van der Wal HH; Emmens JE; Takens J; Samani NJ; Ng LL; Lang CC; van der Meer P; Ter Maaten JM; Damman K; Dickstein K; Cleland JG; Zannad F; Anker SD; Metra M; van der Harst P; de Boer RA; van Veldhuisen DJ; Rienstra M; Lam CSP; Voors AA
    Clin Res Cardiol; 2020 Mar; 109(3):331-338. PubMed ID: 31263996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive Properties of Biomarkers GDF-15, NTproBNP, and hs-TnT for Morbidity and Mortality in Patients With Type 2 Diabetes With Nephropathy.
    Bidadkosh A; Lambooy SPH; Heerspink HJ; Pena MJ; Henning RH; Buikema H; Deelman LE
    Diabetes Care; 2017 Jun; 40(6):784-792. PubMed ID: 28341782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide, Troponin-T, and Growth-Differentiation Factor 15 in Adult Congenital Heart Disease.
    Baggen VJ; van den Bosch AE; Eindhoven JA; Schut AW; Cuypers JA; Witsenburg M; de Waart M; van Schaik RH; Zijlstra F; Boersma E; Roos-Hesselink JW
    Circulation; 2017 Jan; 135(3):264-279. PubMed ID: 27832613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth differentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients.
    Heringlake M; Charitos EI; Gatz N; Käbler JH; Beilharz A; Holz D; Schön J; Paarmann H; Petersen M; Hanke T
    J Am Coll Cardiol; 2013 Feb; 61(6):672-81. PubMed ID: 23391200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease.
    Chang SA; Khakh P; Janzen M; Lee T; Kiess M; Rychel V; Grewal J
    Circ Heart Fail; 2022 Aug; 15(8):e009018. PubMed ID: 35904022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure.
    Gaggin HK; Szymonifka J; Bhardwaj A; Belcher A; De Berardinis B; Motiwala S; Wang TJ; Januzzi JL
    JACC Heart Fail; 2014 Feb; 2(1):65-72. PubMed ID: 24622120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study.
    Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E
    Circulation; 2011 May; 123(19):2101-10. PubMed ID: 21536998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction.
    Mendez Fernandez AB; Ferrero-Gregori A; Garcia-Osuna A; Mirabet-Perez S; Pirla-Buxo MJ; Cinca-Cuscullola J; Ordonez-Llanos J; Roig Minguell E
    ESC Heart Fail; 2020 Oct; 7(5):2223-2229. PubMed ID: 32589369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serially measured high-sensitivity cardiac troponin T, N-terminal-pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 for risk assessment after acute coronary syndrome: the BIOMArCS cohort.
    Gürgöze MT; Akkerhuis KM; Oemrawsingh RM; Umans VAWM; Kietselaer B; Schotborgh CE; Ronner E; Lenderink T; Aksoy I; van der Harst P; Asselbergs FW; Maas AC; Oude Ophuis AJ; Krenning B; de Winter RJ; The SHK; Wardeh AJ; Hermans WRM; Cramer GE; van Gorp I; de Rijke YB; van Schaik RHN; Boersma E
    Eur Heart J Acute Cardiovasc Care; 2023 Jul; 12(7):451-461. PubMed ID: 37096818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
    Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GDF-15 in solid vs non-solid treatment-naïve malignancies.
    Arfsten H; Cho A; Freitag C; Raderer M; Goliasch G; Bartko PE; Wurm R; Strunk G; Gisslinger H; Marosi C; Kornek G; Zielinski C; Hülsmann M; Pavo N
    Eur J Clin Invest; 2019 Nov; 49(11):e13168. PubMed ID: 31463975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between growth differentiation factor-15 and chronic heart failure in coronary atherosclerosis patients.
    Zhu ZD; Sun T
    Genet Mol Res; 2015 Mar; 14(1):2225-33. PubMed ID: 25867369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Panel of emerging cardiac biomarkers contributes for prognosis rather than diagnosis in chronic heart failure.
    Jungbauer CG; Riedlinger J; Block D; Stadler S; Birner C; Buesing M; König W; Riegger G; Maier L; Luchner A
    Biomark Med; 2014; 8(6):777-89. PubMed ID: 25224934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Growth differentiation factor 15 in a community-based sample: age-dependent reference limits and prognostic impact.
    Doerstling S; Hedberg P; Öhrvik J; Leppert J; Henriksen E
    Ups J Med Sci; 2018 Jun; 123(2):86-93. PubMed ID: 29714603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NT-ProBNP and high-sensitivity troponin T as screening tests for subclinical chronic heart failure in a general population.
    Averina M; Stylidis M; Brox J; Schirmer H
    ESC Heart Fail; 2022 Jun; 9(3):1954-1962. PubMed ID: 35322586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary N-terminal pro-B-type natriuretic peptide as a biomarker for cardiovascular events in a general Japanese population: the Hisayama Study.
    Yamasaki K; Hata J; Ide T; Nagata T; Sakata S; Yoshida D; Honda T; Hirakawa Y; Nakano T; Kitazono T; Tsutsui H; Ninomiya T
    Environ Health Prev Med; 2021 Apr; 26(1):47. PubMed ID: 33845756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure.
    Hauser JA; Demyanets S; Rusai K; Goritschan C; Weber M; Panesar D; Rindler L; Taylor AM; Marculescu R; Burch M; Wojta J; Michel-Behnke I
    Heart; 2016 Oct; 102(20):1633-9. PubMed ID: 27220692
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth Differentiation Factor-15, High-Sensitivity Cardiac Troponin T, and N-Terminal pro-B-type Natriuretic Peptide for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy.
    Roy DC; Wang TF; Mallick R; Carrier M; Mollanji E; Liu P; Zhang L; Hawken S; Wells P
    Thromb Haemost; 2022 Jul; 122(7):1169-1176. PubMed ID: 35263789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NT-proBNP and troponin T and risk of rapid kidney function decline and incident CKD in elderly adults.
    Bansal N; Katz R; Dalrymple L; de Boer I; DeFilippi C; Kestenbaum B; Park M; Sarnak M; Seliger S; Shlipak M
    Clin J Am Soc Nephrol; 2015 Feb; 10(2):205-14. PubMed ID: 25605700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.